All Phenotypes Tg(CD2-icre)4Kio MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Tg(CD2-icre)4Kio
transgene insertion 4, Dimitris Kioussis
MGI:2449947

Summary

19 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gimap1^tm1.1Gwb/Gimap1^tm1.1Gwb Tg(CD2-icre)4Kio/0	involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca	MGI:4459839
cn2	Nampt^tm1Oleo/Nampt^tm1Oleo Tg(CD2-icre)4Kio/0	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/10 * CBA/Ca	MGI:3818632
cn3	Septin7^tm1Mgl/Septin7^tm1Mgl Tg(CD2-icre)4Kio/0	involves: 129P2/OlaHsd * C3H * C57BL/6 * C57BL/10 * CBA/Ca	MGI:5660277
cn4	Noc2l^tm1.1Arte/Noc2l^tm1.1Arte Trp53^tm1Brn/Trp53^tm1Brn Tg(CD2-icre)4Kio/0	involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * CBA/Ca	MGI:5662110
cn5	Bcl2l11^tm1.1Ast/Bcl2l11⁺ Pten^tm1Hwu/Pten⁺ Tg(CD2-icre)4Kio/0	involves: 129S1/Sv * 129S4/SvJae * C57BL/10 * CBA/Ca	MGI:3783573
cn6	Ret^tm6.1Vpa/Ret^tm6.2Vpa Tg(CD2-icre)4Kio/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca	MGI:5489749
cn7	Etv6^{tm1(RUNX1)Haho}/Etv6⁺ Tg(CD2-icre)4Kio/0	involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca	MGI:4356081
cn8	Gmnn^tm1.1Kio/Gmnn^tm1.2Kio Tg(CD2-icre)4Kio/0	involves: 129S4/SvJae * C57BL/10 * CBA/Ca	MGI:4456379
cn9	Rr7^tm3.1Kio/Rr7⁺ Tg(CD2-icre)4Kio/0	involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca	MGI:5305075
cn10	Pten^tm1Hwu/Pten^tm1Hwu Tg(CD2-icre)4Kio/0	involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca	MGI:5688871
cn11	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Pten^tm1Hwu/Pten^tm1Hwu Tg(CD2-icre)4Kio/0	involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca	MGI:5688869
cn12	Ikzf1^tm3Kge/Ikzf1^tm3Kge Tg(CD2-icre)4Kio/?	involves: C57BL/10 * CBA/Ca	MGI:5698879
cn13	Syk^tm1.1Nns/Syk^tm1.1Nns Tg(CD2-icre)4Kio/0	involves: C57BL/10 * CBA/Ca	MGI:5314237
cn14	Noc2l^tm1.1Arte/Noc2l^tm1.1Arte Tg(CD2-icre)4Kio/0	involves: C57BL/6 * C57BL/10 * CBA/Ca	MGI:5662109
cn15	Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky} Tg(CD2-icre)4Kio/0	involves: C57BL/6 * C57BL/10 * CBA/Ca	MGI:3783575
cn16	Gimap6^tm1.1Gwb/Gimap6^tm1.1Gwb Tg(CD2-icre)4Kio/0	involves: C57BL/6 * C57BL/10 * CBA/Ca	MGI:6160464
cn17	Mir146^tm1.1Lfl/Mir146^tm1.1Lfl Tg(CD2-icre)4Kio/0	involves: C57BL/6 * C57BL/10 * CBA/Ca	MGI:6360065
cn18	Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/Gt(ROSA)26Sor⁺ Tg(CD2-icre)4Kio/0	involves: C57BL/6 * C57BL/10 * CBA/Ca	MGI:3783574
cn19	Zfp36l1^tm1.1Tnr/Zfp36l1^tm1.1Tnr Zfp36l2^tm1.1Tnr/Zfp36l2^tm1.1Tnr Tg(CD2-icre)4Kio/0	involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL	MGI:4819157

Allelic Composition	Gimap1^tm1.1Gwb/Gimap1^tm1.1Gwb Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gimap1^tm1.1Gwb mutation (0 available); any Gimap1 mutation (8 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

decreased lymphocyte cell number ( J:160782 )

• the overall spleenic cellularity is reduced by approximately 40%

• the lymph node cellualrity is severely reduced

decreased B cell number ( J:160782 )

• in lymph nodes

decreased transitional stage T2 B cell number ( J:160782 )

decreased B-1a cell number ( J:160782 )

• in peritoneum

decreased B-1b cell number ( J:160782 )

• in peritoneum

decreased B-2 B cell number ( J:160782 )

• in peritoneum

decreased follicular B cell number ( J:160782 )

decreased marginal zone B cell number ( J:160782 )

decreased T cell number ( J:160782 )

• in peritoneum and blood

decreased thymocyte number ( J:160782 )

decreased CD4-positive, alpha-beta T cell number ( J:160782 )

• in spleen and lymph node and the CD4 single positive subset in the thymus

decreased CD8-positive, alpha-beta T cell number ( J:160782 )

• in spleen and lymph node and the CD8 single positive subset in the thymus

abnormal CD4-positive, alpha-beta T cell physiology ( J:160782 )

• decreased thymocyte survival in culture

abnormal CD8-positive, alpha-beta T cell physiology ( J:160782 )

• a trend towards decreased thymocyte survival in culture

immune system

decreased lymphocyte cell number ( J:160782 )

• the overall spleenic cellularity is reduced by approximately 40%

• the lymph node cellualrity is severely reduced

decreased B cell number ( J:160782 )

• in lymph nodes

decreased transitional stage T2 B cell number ( J:160782 )

decreased B-1a cell number ( J:160782 )

• in peritoneum

decreased B-1b cell number ( J:160782 )

• in peritoneum

decreased B-2 B cell number ( J:160782 )

• in peritoneum

decreased follicular B cell number ( J:160782 )

decreased marginal zone B cell number ( J:160782 )

decreased T cell number ( J:160782 )

• in peritoneum and blood

decreased thymocyte number ( J:160782 )

decreased CD4-positive, alpha-beta T cell number ( J:160782 )

• in spleen and lymph node and the CD4 single positive subset in the thymus

decreased CD8-positive, alpha-beta T cell number ( J:160782 )

• in spleen and lymph node and the CD8 single positive subset in the thymus

abnormal CD4-positive, alpha-beta T cell physiology ( J:160782 )

• decreased thymocyte survival in culture

abnormal CD8-positive, alpha-beta T cell physiology ( J:160782 )

• a trend towards decreased thymocyte survival in culture

endocrine/exocrine glands

decreased thymocyte number ( J:160782 )

Allelic Composition	Nampt^tm1Oleo/Nampt^tm1Oleo Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nampt^tm1Oleo mutation (1 available); any Nampt mutation (91 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

thymus hypoplasia ( J:141448 )

• thymic cell numbers are decreased 95% compared to in wild-type mice

decreased B cell number ( J:141448 )

• mice exhibit a near complete lack of peripheral B cells

decreased T cell number ( J:141448 )

• mice exhibit a near complete lack of peripheral T cells

decreased double-negative T cell number ( J:141448 )

• mice exhibit a near complete absence of double negative T cells compared to in wild-type mice

hematopoietic system

thymus hypoplasia ( J:141448 )

• thymic cell numbers are decreased 95% compared to in wild-type mice

decreased B cell number ( J:141448 )

• mice exhibit a near complete lack of peripheral B cells

decreased T cell number ( J:141448 )

• mice exhibit a near complete lack of peripheral T cells

decreased double-negative T cell number ( J:141448 )

• mice exhibit a near complete absence of double negative T cells compared to in wild-type mice

endocrine/exocrine glands

thymus hypoplasia ( J:141448 )

• thymic cell numbers are decreased 95% compared to in wild-type mice

Allelic Composition	Septin7^tm1Mgl/Septin7^tm1Mgl Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129P2/OlaHsd * C3H * C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Septin7^tm1Mgl mutation (0 available); any Septin7 mutation (36 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

immune system phenotype ( J:223786 )

N	• mice exhibit normal numbers of peripheral blood cells • myeloid cells and lymphoid cells exhibit normal cytokinesis

Allelic Composition	Noc2l^tm1.1Arte/Noc2l^tm1.1Arte Trp53^tm1Brn/Trp53^tm1Brn Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Noc2l^tm1.1Arte mutation (0 available); any Noc2l mutation (19 available)
Tg(CD2-icre)4Kio mutation (4 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

hematopoietic system phenotype ( J:216490 )

• rescue of the CD4+CD8+ double positive thymocyte developmental defect

• significant increase in the number of single positive thymocytes in comparison to mutant mice wild-type for Trp53

• significant recovery of DN3L cells close to levels in control mice

• significant increase in the number of late pro-B cells in comparison to mutant mice wild-type for Trp53

decreased pre-B cell number ( J:216490 )

• numbers of pre-B (IgM+B220+CD19+CD43-) are not increased by the absence of Trp53 expression

immune system

decreased pre-B cell number ( J:216490 )

• numbers of pre-B (IgM+B220+CD19+CD43-) are not increased by the absence of Trp53 expression

Allelic Composition	Bcl2l11^tm1.1Ast/Bcl2l11⁺ Pten^tm1Hwu/Pten⁺ Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129S1/Sv * 129S4/SvJae * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl2l11^tm1.1Ast mutation (4 available); any Bcl2l11 mutation (32 available)
Pten^tm1Hwu mutation (16 available); any Pten mutation (81 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

increased germinal center B cell number ( J:133215 )

• at 20 to 28 weeks of age, mice exhibit increased germinal center B cell number compared to controls but not as much as in Gt(ROSA)26Sor^tm3Rsky/Gt(ROSA)26Sor^tm3Rsky/ Tg(CD2-cre)1Kio mice

abnormal T cell number ( J:133215 )

• at 20 to 28 weeks of age, mice accumulate more antigen-experienced T cells than in control mice but not as much as in Gt(ROSA)26Sor^tm3Rsky/Gt(ROSA)26Sor^tm3Rsky/ Tg(CD2-cre)1Kio mice

hematopoietic system

increased germinal center B cell number ( J:133215 )

• at 20 to 28 weeks of age, mice exhibit increased germinal center B cell number compared to controls but not as much as in Gt(ROSA)26Sor^tm3Rsky/Gt(ROSA)26Sor^tm3Rsky/ Tg(CD2-cre)1Kio mice

abnormal T cell number ( J:133215 )

• at 20 to 28 weeks of age, mice accumulate more antigen-experienced T cells than in control mice but not as much as in Gt(ROSA)26Sor^tm3Rsky/Gt(ROSA)26Sor^tm3Rsky/ Tg(CD2-cre)1Kio mice

Allelic Composition	Ret^tm6.1Vpa/Ret^tm6.2Vpa Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ret^tm6.1Vpa mutation (0 available); any Ret mutation (53 available)
Ret^tm6.2Vpa mutation (0 available); any Ret mutation (53 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

hematopoietic system phenotype ( J:195828 )

N	• bone marrow cells are capable of normal

immune system

immune system phenotype ( J:195828 )

N	• mice exhibit normal fetal and adult T cell development

Allelic Composition	Etv6^{tm1(RUNX1)Haho}/Etv6⁺ Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Etv6^{tm1(RUNX1)Haho} mutation (1 available); any Etv6 mutation (142 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

immune system phenotype ( J:151639 )

N	• T and B cell development is normal

Allelic Composition	Gmnn^tm1.1Kio/Gmnn^tm1.2Kio Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129S4/SvJae * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gmnn^tm1.1Kio mutation (0 available); any Gmnn mutation (26 available)
Gmnn^tm1.2Kio mutation (0 available); any Gmnn mutation (26 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

decreased T cell proliferation ( J:159657 )

• in response to mitogenic stimulation (anti-CD3 plus anti-CD28, or PDBU and ionomycin or Con A), T cells exhibit decreased proliferation compared with similarly treated control cells

• anti-CD3 and anti-CD28-treated T cells exhibit an increase in percentage of cells at the G2/M phase and accumulate in G2 phase compared with similarly treated control cells

• T cells fail to exhibit spontaneous proliferation in a T cell depleted mouse with reduced CD8 T cells compared with control cells

• however, T cells exhibit normal apoptosis and entry into S phase

decreased thymocyte number ( J:159657 )

decreased DN1 thymic pro-T cell number ( J:159657 )

• moderate

decreased DN4 thymocyte number ( J:159657 )

• moderate

decreased double-positive T cell number ( J:159657 )

• moderate

decreased CD4-positive, alpha-beta T cell number ( J:159657 )

• mice exhibit a reduction of CD4+, CD4+CD62L-, and CD4+CD44^hi cells compared with control mice

decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number ( J:159657 )

decreased CD8-positive, alpha-beta T cell number ( J:159657 )

• mice exhibit a reduction of CD8+ and CD8+CD62L- cells compared with control mice

decreased memory T cell number ( J:159657 )

hematopoietic system

decreased T cell proliferation ( J:159657 )

• in response to mitogenic stimulation (anti-CD3 plus anti-CD28, or PDBU and ionomycin or Con A), T cells exhibit decreased proliferation compared with similarly treated control cells

• anti-CD3 and anti-CD28-treated T cells exhibit an increase in percentage of cells at the G2/M phase and accumulate in G2 phase compared with similarly treated control cells

• T cells fail to exhibit spontaneous proliferation in a T cell depleted mouse with reduced CD8 T cells compared with control cells

• however, T cells exhibit normal apoptosis and entry into S phase

decreased thymocyte number ( J:159657 )

decreased DN1 thymic pro-T cell number ( J:159657 )

• moderate

decreased DN4 thymocyte number ( J:159657 )

• moderate

decreased double-positive T cell number ( J:159657 )

• moderate

decreased CD4-positive, alpha-beta T cell number ( J:159657 )

• mice exhibit a reduction of CD4+, CD4+CD62L-, and CD4+CD44^hi cells compared with control mice

decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number ( J:159657 )

decreased CD8-positive, alpha-beta T cell number ( J:159657 )

• mice exhibit a reduction of CD8+ and CD8+CD62L- cells compared with control mice

decreased memory T cell number ( J:159657 )

endocrine/exocrine glands

decreased thymocyte number ( J:159657 )

decreased DN1 thymic pro-T cell number ( J:159657 )

• moderate

decreased DN4 thymocyte number ( J:159657 )

• moderate

cellular

decreased T cell proliferation ( J:159657 )

• in response to mitogenic stimulation (anti-CD3 plus anti-CD28, or PDBU and ionomycin or Con A), T cells exhibit decreased proliferation compared with similarly treated control cells

• anti-CD3 and anti-CD28-treated T cells exhibit an increase in percentage of cells at the G2/M phase and accumulate in G2 phase compared with similarly treated control cells

• T cells fail to exhibit spontaneous proliferation in a T cell depleted mouse with reduced CD8 T cells compared with control cells

• however, T cells exhibit normal apoptosis and entry into S phase

Allelic Composition	Rr7^tm3.1Kio/Rr7⁺ Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rr7^tm3.1Kio mutation (0 available); any Rr7 mutation (0 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

immune system phenotype ( J:179326 )

N	• mice exhibit normal expression of Cd8a and Cd8b

Allelic Composition	Pten^tm1Hwu/Pten^tm1Hwu Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pten^tm1Hwu mutation (16 available); any Pten mutation (81 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

enlarged thymus ( J:216983 )

• at 6-8 weeks of age

endocrine/exocrine glands

enlarged thymus ( J:216983 )

• at 6-8 weeks of age

immune system

enlarged thymus ( J:216983 )

• at 6-8 weeks of age

Allelic Composition	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Pten^tm1Hwu/Pten^tm1Hwu Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pkn3^tm1.1Mrl mutation (0 available); any Pkn3 mutation (54 available)
Pten^tm1Hwu mutation (16 available); any Pten mutation (81 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:216983 )

N	• thymus weight is similar to controls at 6-8 weeks of age unlike in mutant mice wild-type for Pkn3

Allelic Composition	Ikzf1^tm3Kge/Ikzf1^tm3Kge Tg(CD2-icre)4Kio/?
Genetic Background	involves: C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ikzf1^tm3Kge mutation (0 available); any Ikzf1 mutation (30 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

abnormal B cell physiology ( J:209927 )

• large pre-B cells fail to differentiate further in culture

• grow better than controls on a bone marrow stroma, 2-10 fold more cells in the cell cycle

• greater colony forming potential on bone marrow stroma than control cells

• pre-B cells unable to migrate in response to CXCL12

neoplasm

increased T cell derived lymphoma incidence ( J:209927 )

• rapid development of T lymphoid neoplasms

immune system

abnormal B cell physiology ( J:209927 )

• large pre-B cells fail to differentiate further in culture

• grow better than controls on a bone marrow stroma, 2-10 fold more cells in the cell cycle

• greater colony forming potential on bone marrow stroma than control cells

• pre-B cells unable to migrate in response to CXCL12

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:209927 )

• rapid development of T lymphoid neoplasms

Allelic Composition	Syk^tm1.1Nns/Syk^tm1.1Nns Tg(CD2-icre)4Kio/0
Genetic Background	involves: C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Syk^tm1.1Nns mutation (0 available); any Syk mutation (42 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

mortality/aging ( J:181715 )

N	• mice exhibit normal perinatal survival

immune system

immune system phenotype ( J:181715 )

N	• mice exhibit normal lymphatic vessels

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:181715 )

N	• mice do not exhibit edema

Allelic Composition	Noc2l^tm1.1Arte/Noc2l^tm1.1Arte Tg(CD2-icre)4Kio/0
Genetic Background	involves: C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Noc2l^tm1.1Arte mutation (0 available); any Noc2l mutation (19 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

increased thymocyte apoptosis ( J:216490 )

• increased apoptosis in DN3 thymocytes

abnormal T cell proliferation ( J:216490 )

• retention of the DN3 cell population indicating a block between the DN3 and DN4 stages of development

abnormal thymus morphology ( J:216490 )

• lack a distinct cortex-medulla compartmentalization

abnormal thymus cell ratio ( J:216490 )

• approximately 98% of cells recovered from the thymi are double negative

small thymus ( J:216490 )

• at 5-6 weeks of age

thymus hypoplasia ( J:216490 )

• dramatic reduction in cellularity at 5-6 weeks of age

decreased DN3 thymocyte number ( J:216490 )

• decrease in the number of DN3L (larger cycling) cells with a preservation of the DN3E (small, resting G1) population

decreased DN4 thymocyte number ( J:216490 )

• absent

abnormal thymus involution ( J:216490 )

• severe early involution is seen at 5-6 weeks of age

abnormal B cell morphology ( J:216490 )

decreased immature B cell number ( J:216490 )

• dramatic decrease in B220+IgM+ immature B cells in the bone marrow

decreased pro-B cell number ( J:216490 )

• developmental block between very early pro-B cells (B220+CD43+CD19-) and later pro-B (B220+CD43+CD19+) stage

decreased mature B cell number ( J:216490 )

• decrease in B220+IgM+ mature B cells

decreased pre-B cell number ( J:216490 )

• significant decrease in the B220+CD43- pre-B population

abnormal T cell morphology ( J:216490 )

decreased double-positive T cell number ( J:216490 )

• almost a complete absence of double positive T cells in the thymus

arrested T cell differentiation ( J:216490 )

• retention of the DN3 cell population indicating a block between the DN3 and DN4 stages of development

decreased alpha-beta T cell number ( J:216490 )

• decrease in the number of TCR-Beta producing cells

• however, the gamma-delta cell population is preserved

absent T cells ( J:216490 )

• absence of mature splenic T cells at P5

decreased single-positive T cell number ( J:216490 )

• decrease in the number of single positive CD4+ and CD8+ cells

spleen hypoplasia ( J:216490 )

• decrease in T cells and B220+IgM+ mature B cells

endocrine/exocrine glands

increased thymocyte apoptosis ( J:216490 )

• increased apoptosis in DN3 thymocytes

abnormal thymus morphology ( J:216490 )

• lack a distinct cortex-medulla compartmentalization

abnormal thymus cell ratio ( J:216490 )

• approximately 98% of cells recovered from the thymi are double negative

small thymus ( J:216490 )

• at 5-6 weeks of age

thymus hypoplasia ( J:216490 )

• dramatic reduction in cellularity at 5-6 weeks of age

decreased DN3 thymocyte number ( J:216490 )

• decrease in the number of DN3L (larger cycling) cells with a preservation of the DN3E (small, resting G1) population

decreased DN4 thymocyte number ( J:216490 )

• absent

abnormal thymus involution ( J:216490 )

• severe early involution is seen at 5-6 weeks of age

immune system

increased thymocyte apoptosis ( J:216490 )

• increased apoptosis in DN3 thymocytes

abnormal T cell proliferation ( J:216490 )

• retention of the DN3 cell population indicating a block between the DN3 and DN4 stages of development

abnormal thymus morphology ( J:216490 )

• lack a distinct cortex-medulla compartmentalization

abnormal thymus cell ratio ( J:216490 )

• approximately 98% of cells recovered from the thymi are double negative

small thymus ( J:216490 )

• at 5-6 weeks of age

thymus hypoplasia ( J:216490 )

• dramatic reduction in cellularity at 5-6 weeks of age

decreased DN3 thymocyte number ( J:216490 )

• decrease in the number of DN3L (larger cycling) cells with a preservation of the DN3E (small, resting G1) population

decreased DN4 thymocyte number ( J:216490 )

• absent

abnormal thymus involution ( J:216490 )

• severe early involution is seen at 5-6 weeks of age

abnormal B cell morphology ( J:216490 )

decreased immature B cell number ( J:216490 )

• dramatic decrease in B220+IgM+ immature B cells in the bone marrow

decreased pro-B cell number ( J:216490 )

• developmental block between very early pro-B cells (B220+CD43+CD19-) and later pro-B (B220+CD43+CD19+) stage

decreased mature B cell number ( J:216490 )

• decrease in B220+IgM+ mature B cells

decreased pre-B cell number ( J:216490 )

• significant decrease in the B220+CD43- pre-B population

abnormal T cell morphology ( J:216490 )

decreased double-positive T cell number ( J:216490 )

• almost a complete absence of double positive T cells in the thymus

arrested T cell differentiation ( J:216490 )

• retention of the DN3 cell population indicating a block between the DN3 and DN4 stages of development

decreased alpha-beta T cell number ( J:216490 )

• decrease in the number of TCR-Beta producing cells

• however, the gamma-delta cell population is preserved

absent T cells ( J:216490 )

• absence of mature splenic T cells at P5

decreased single-positive T cell number ( J:216490 )

• decrease in the number of single positive CD4+ and CD8+ cells

spleen hypoplasia ( J:216490 )

• decrease in T cells and B220+IgM+ mature B cells

cellular

abnormal cell cycle ( J:216490 )

• DN3 thymocytes show a block at the G1/S phase of the cell cycle

increased thymocyte apoptosis ( J:216490 )

• increased apoptosis in DN3 thymocytes

abnormal T cell proliferation ( J:216490 )

• retention of the DN3 cell population indicating a block between the DN3 and DN4 stages of development

Allelic Composition	Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky} Tg(CD2-icre)4Kio/0
Genetic Background	involves: C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky} mutation (1 available); any Gt(ROSA)26Sor mutation (942 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:133215 )

• all mice die by 55 weeks of age

immune system

immune system phenotype ( J:133215 )

N	• despite increased immunoglobulin, cytokine levels in the blood are normal

abnormal immune system morphology ( J:133215 )

increased spleen weight ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

spleen hyperplasia ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

abnormal T cell differentiation ( J:133215 )

• prior to 14 weeks of age, mice exhibit a 2-fold higher percentage of thymocytes at the double negative stage compared to in wild-type mice

• however, the total number of thymocytes is unchanged

increased lymphocyte cell number ( J:133215 )

• at 5 weeks of age

increased B cell number ( J:133215 )

increased germinal center B cell number ( J:133215 )

• in the spleen and peripheral lymph nodes

increased B-1a cell number ( J:133215 )

• mice exhibit more CD19+B220^loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice

increased CD8-positive, alpha-beta T cell number ( J:133215 )

abnormal B cell morphology ( J:133215 )

• spleen and lymph node B cells exhibit increased cell size compared to in wild-type mice

abnormal CD4-positive, alpha beta T cell morphology ( J:133215 )

• CD4+ T cells exhibit increased proliferation and survival following stimulation with CD3 alone unlike wild-type cells

increased CD4-positive, alpha-beta T cell number ( J:133215 )

decreased spleen red pulp amount ( J:133215 )

intermingled spleen red and white pulp ( J:133215 )

abnormal spleen marginal zone morphology ( J:133215 )

• the spleen marginal zone is disrupted unlike in wild-type mice

decreased marginal zone B cell number ( J:133215 )

increased spleen white pulp amount ( J:133215 )

enlarged lymph nodes ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

lymph node hyperplasia ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

abnormal immune system physiology ( J:133215 )

• mice exhibit massive infiltration of lymphocytes into the salivary glands and lungs with some infiltration of the kidneys unlike in wild-type mice

abnormal B cell activation ( J:133215 )

• B cells are more resistance than in wild-type mice to Fas-mediated cell death following activation

• activated B cells exhibit enhanced proliferation and survival compared to wild-type cells

increased B cell proliferation ( J:133215 )

• B-2 cell proliferation is enhanced following activation with anti-IgM or lipopolysaccharides unlike in wild-type cells

abnormal immunoglobulin level ( J:133215 )

increased IgG2a level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgG2b level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgG3 level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgM level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

abnormal CD4-positive, alpha-beta T cell physiology ( J:133215 )

• more CD4+ T cells produce IFN-gamma and IL-10 but not IL-4 or TNF than wild-type cells

• CD4+T cells from older mice produce more IFN-gamma and IL-10 than CD4+ T cells from younger mice

abnormal T cell activation ( J:133215 )

• activated T cells exhibit enhanced proliferation and survival compared to wild-type cells

increased anti-double stranded DNA antibody level ( J:133215 )

• at 18 to 25 weeks

increased anti-single stranded DNA antibody level ( J:133215 )

• at 18 to 25 weeks

renal/urinary system

increased urine protein level ( J:133215 )

• in some mice

abnormal glomerular mesangium morphology ( J:133215 )

• a subset of mice show marked accumulation of IgG and the C3d component of complement in the mesangium and segmentally in the periphery of glomeruli

increased mesangial cell number ( J:133215 )

expanded mesangial matrix ( J:133215 )

• mice exhibit mesangial expansion unlike in wild-type mice

renal glomerulus hypertrophy ( J:133215 )

• mice exhibit enlarged renal glomeruli with hypercellularity and mesangial expansion unlike in wild-type mice

pale kidney ( J:133215 )

• in some mice

homeostasis/metabolism

increased urine protein level ( J:133215 )

• in some mice

hematopoietic system

increased spleen weight ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

spleen hyperplasia ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

abnormal T cell differentiation ( J:133215 )

• prior to 14 weeks of age, mice exhibit a 2-fold higher percentage of thymocytes at the double negative stage compared to in wild-type mice

• however, the total number of thymocytes is unchanged

extramedullary hematopoiesis ( J:133215 )

increased lymphocyte cell number ( J:133215 )

• at 5 weeks of age

increased B cell number ( J:133215 )

increased germinal center B cell number ( J:133215 )

• in the spleen and peripheral lymph nodes

increased B-1a cell number ( J:133215 )

• mice exhibit more CD19+B220^loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice

increased CD8-positive, alpha-beta T cell number ( J:133215 )

abnormal B cell morphology ( J:133215 )

• spleen and lymph node B cells exhibit increased cell size compared to in wild-type mice

abnormal CD4-positive, alpha beta T cell morphology ( J:133215 )

• CD4+ T cells exhibit increased proliferation and survival following stimulation with CD3 alone unlike wild-type cells

increased CD4-positive, alpha-beta T cell number ( J:133215 )

decreased spleen red pulp amount ( J:133215 )

intermingled spleen red and white pulp ( J:133215 )

abnormal spleen marginal zone morphology ( J:133215 )

• the spleen marginal zone is disrupted unlike in wild-type mice

decreased marginal zone B cell number ( J:133215 )

increased spleen white pulp amount ( J:133215 )

abnormal B cell activation ( J:133215 )

• B cells are more resistance than in wild-type mice to Fas-mediated cell death following activation

• activated B cells exhibit enhanced proliferation and survival compared to wild-type cells

increased B cell proliferation ( J:133215 )

• B-2 cell proliferation is enhanced following activation with anti-IgM or lipopolysaccharides unlike in wild-type cells

abnormal immunoglobulin level ( J:133215 )

increased IgG2a level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgG2b level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgG3 level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgM level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

abnormal CD4-positive, alpha-beta T cell physiology ( J:133215 )

• more CD4+ T cells produce IFN-gamma and IL-10 but not IL-4 or TNF than wild-type cells

• CD4+T cells from older mice produce more IFN-gamma and IL-10 than CD4+ T cells from younger mice

abnormal T cell activation ( J:133215 )

• activated T cells exhibit enhanced proliferation and survival compared to wild-type cells

growth/size/body

increased spleen weight ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

spleen hyperplasia ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

cellular

increased mesangial cell number ( J:133215 )

increased B cell proliferation ( J:133215 )

• B-2 cell proliferation is enhanced following activation with anti-IgM or lipopolysaccharides unlike in wild-type cells

Allelic Composition	Gimap6^tm1.1Gwb/Gimap6^tm1.1Gwb Tg(CD2-icre)4Kio/0
Genetic Background	involves: C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gimap6^tm1.1Gwb mutation (0 available); any Gimap6 mutation (15 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

abnormal mitochondrial morphology ( J:262059 )

• occasional mitochondrial spheroid observed in Cd4+ T splenocytes by electron microscopy

• significant increase in mitochondrial/cytoplasmic volume ratio in Cd4+ T splenocytes as indicated by electron microscopy

abnormal autophagy ( J:262059 )

• increased levels of Map1lc3b (particularly the LC3-II variant) protein in Cd4+ T cells and Cd8+ T and B cells isolated from spleen, indicating increased number of autophagosomes

• increased number of autophagosomes per Cd4+ T splenocyte as indicated by electron microscopy

abnormal mitophagy ( J:262059 )

• significant increase in mitochondrial/cytoplasmic volume ratio in Cd4+ T splenocytes as indicated by electron microscopy

increased T cell apoptosis ( J:262059 )

• of Cd4+ T splenocytes as indicated by annexin V+ DAPI- staining

• younger age profile of Cd4+ T splenocytes as indicated by Cd24+ staining

hematopoietic system

abnormal leukocyte morphology ( J:262059 )

• increase in cytoplasmic surface area per nucleated Cd4+ T splenocyte as indicated by electron microscopy

• increase in Cd4+ T cells and Cd8+ T splenocyte diameter

decreased B cell number ( J:262059 )

• significant reduction in recirculating B cell percentage in bone marrow

increased B cell number ( J:262059 )

• significant increase in percentages and numbers of follicular, marginal zone, T1, T2 and T3 B splenocytes

• significant increase in percentage, but not number, of mature B cells in lymph nodes

decreased T cell number ( J:262059 )

• 50-70% reduction in percentage and number of Cd4+ and Cd8+ T cells in spleen and lymph nodes

• Cd4- Cd8-, Cd4+ Cd8+, Cd4+ and Cd8+ T cell percentages in thymus

abnormal T cell physiology ( J:262059 )

• shift from Cd62l(high) Cd44(low) to Cd62l(low) Cd44(high) cell surface expression on splenic and lymph node Cd4+ T cells

• reduction in Cd44(high) fraction of splenic and lymph node Cd8+ T cells

• Cd69 surface expression on Cd4+ and Cd8+ T splenocytes

increased T cell apoptosis ( J:262059 )

• of Cd4+ T splenocytes as indicated by annexin V+ DAPI- staining

• younger age profile of Cd4+ T splenocytes as indicated by Cd24+ staining

immune system

abnormal leukocyte morphology ( J:262059 )

• increase in cytoplasmic surface area per nucleated Cd4+ T splenocyte as indicated by electron microscopy

• increase in Cd4+ T cells and Cd8+ T splenocyte diameter

decreased B cell number ( J:262059 )

• significant reduction in recirculating B cell percentage in bone marrow

increased B cell number ( J:262059 )

• significant increase in percentages and numbers of follicular, marginal zone, T1, T2 and T3 B splenocytes

• significant increase in percentage, but not number, of mature B cells in lymph nodes

decreased T cell number ( J:262059 )

• 50-70% reduction in percentage and number of Cd4+ and Cd8+ T cells in spleen and lymph nodes

• Cd4- Cd8-, Cd4+ Cd8+, Cd4+ and Cd8+ T cell percentages in thymus

abnormal T cell physiology ( J:262059 )

• shift from Cd62l(high) Cd44(low) to Cd62l(low) Cd44(high) cell surface expression on splenic and lymph node Cd4+ T cells

• reduction in Cd44(high) fraction of splenic and lymph node Cd8+ T cells

• Cd69 surface expression on Cd4+ and Cd8+ T splenocytes

increased T cell apoptosis ( J:262059 )

• of Cd4+ T splenocytes as indicated by annexin V+ DAPI- staining

• younger age profile of Cd4+ T splenocytes as indicated by Cd24+ staining

homeostasis/metabolism

abnormal autophagy ( J:262059 )

• increased levels of Map1lc3b (particularly the LC3-II variant) protein in Cd4+ T cells and Cd8+ T and B cells isolated from spleen, indicating increased number of autophagosomes

• increased number of autophagosomes per Cd4+ T splenocyte as indicated by electron microscopy

abnormal mitophagy ( J:262059 )

• significant increase in mitochondrial/cytoplasmic volume ratio in Cd4+ T splenocytes as indicated by electron microscopy

Allelic Composition	Mir146^tm1.1Lfl/Mir146^tm1.1Lfl Tg(CD2-icre)4Kio/0
Genetic Background	involves: C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mir146^tm1.1Lfl mutation (1 available); any Mir146 mutation (9 available)
Tg(CD2-icre)4Kio mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

increased germinal center B cell number ( J:266124 )

• following immunization with sheep red blood cells similar to in B cell conditional knock-outs

increased T follicular helper cell number ( J:266124 )

• following immunization with sheep red blood cells

hematopoietic system

increased germinal center B cell number ( J:266124 )

• following immunization with sheep red blood cells similar to in B cell conditional knock-outs

increased T follicular helper cell number ( J:266124 )

• following immunization with sheep red blood cells

Allelic Composition	Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/Gt(ROSA)26Sor⁺ Tg(CD2-icre)4Kio/0
Genetic Background	involves: C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

decreased marginal zone B cell number ( J:133215 )

increased B-1a cell number ( J:133215 )

• mice exhibit more CD19+B220^loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice

hematopoietic system

decreased marginal zone B cell number ( J:133215 )

increased B-1a cell number ( J:133215 )

• mice exhibit more CD19+B220^loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice

Allelic Composition	Zfp36l1^tm1.1Tnr/Zfp36l1^tm1.1Tnr Zfp36l2^tm1.1Tnr/Zfp36l2^tm1.1Tnr Tg(CD2-icre)4Kio/0
Genetic Background	involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CD2-icre)4Kio mutation (4 available)
Zfp36l1^tm1.1Tnr mutation (0 available); any Zfp36l1 mutation (9 available)
Zfp36l2^tm1.1Tnr mutation (0 available); any Zfp36l2 mutation (20 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:162388 )

• by 6 months of age, 90% of the mutant mice die or are humanely killed because of their ill health

neoplasm

increased T cell derived lymphoma incidence ( J:162388 )

• all mutant mice develop thymic tumors

• thymic tumors have high CD8 expression, with variable CD4 expression

• high expression of heat-stable antigen (CD24) but do not have surface expression of the TCR beta-chain (TCRbeta)

• most but not all tumors have intracellular expression of TCRbeta

• Notch1 mutation is present in a minority of tumors and affected mainly the heterodimerization domain (25%) rather than the PEST domain (8%)

• primary tumor cells cultured in vitro are Notch1 dependent and killed by Zfp36l1 re-expression

increased leukemia incidence ( J:162388 )

• development of T cell acute lymphoblastic leukemia

• circulating lymphoblasts in peripheral blood

• tumor cells in thymus, spleen, lymph node and bone marrow

• predominantly oligoclonal

• corresponding to the CD8+ immature single-positive (CD8iSP) and double-positive (DP) stages of thymic development

immune system

abnormal thymus development ( J:162388 )

• perturbed thymopoiesis before tumor development

• thymic atrophy at 3 and 8 weeks of age

• gradual expansion of the CD8iSP population (CD8+CD4_CD24hi, membrane TCRbeta negative) in both proportion and absolute number by 13 weeks

• less progression from double-negative 2 (DN2) (CD44+CD25+) to DN3 (CD44_CD25+)

• decreased proportion of DN thymocytes with icTCRbeta expression

• only 30% of CD8iSP cells and 90% of DP cells have icTCRbeta expression

thymus atrophy ( J:162388 )

• thymic atrophy at 3 and 8 weeks of age

• total thymic cellularity is approximately 50% that of control mice

enlarged spleen ( J:162388 )

• many mutant mice have splenomegaly

enlarged lymph nodes ( J:162388 )

• many mutant mice have lymphadenopathy

cellular

increased cell proliferation ( J:162388 )

• increased cellular proliferation by EdU staining in thymic populations from mice aged 5 and 10 weeks old

hematopoietic system

abnormal thymus development ( J:162388 )

• perturbed thymopoiesis before tumor development

• thymic atrophy at 3 and 8 weeks of age

• gradual expansion of the CD8iSP population (CD8+CD4_CD24hi, membrane TCRbeta negative) in both proportion and absolute number by 13 weeks

• less progression from double-negative 2 (DN2) (CD44+CD25+) to DN3 (CD44_CD25+)

• decreased proportion of DN thymocytes with icTCRbeta expression

• only 30% of CD8iSP cells and 90% of DP cells have icTCRbeta expression

thymus atrophy ( J:162388 )

• thymic atrophy at 3 and 8 weeks of age

• total thymic cellularity is approximately 50% that of control mice

enlarged spleen ( J:162388 )

• many mutant mice have splenomegaly

endocrine/exocrine glands

abnormal thymus development ( J:162388 )

• perturbed thymopoiesis before tumor development

• thymic atrophy at 3 and 8 weeks of age

• gradual expansion of the CD8iSP population (CD8+CD4_CD24hi, membrane TCRbeta negative) in both proportion and absolute number by 13 weeks

• less progression from double-negative 2 (DN2) (CD44+CD25+) to DN3 (CD44_CD25+)

• decreased proportion of DN thymocytes with icTCRbeta expression

• only 30% of CD8iSP cells and 90% of DP cells have icTCRbeta expression

thymus atrophy ( J:162388 )

• thymic atrophy at 3 and 8 weeks of age

• total thymic cellularity is approximately 50% that of control mice

increased T cell derived lymphoma incidence ( J:162388 )

• all mutant mice develop thymic tumors

• thymic tumors have high CD8 expression, with variable CD4 expression

• high expression of heat-stable antigen (CD24) but do not have surface expression of the TCR beta-chain (TCRbeta)

• most but not all tumors have intracellular expression of TCRbeta

• Notch1 mutation is present in a minority of tumors and affected mainly the heterodimerization domain (25%) rather than the PEST domain (8%)

• primary tumor cells cultured in vitro are Notch1 dependent and killed by Zfp36l1 re-expression

growth/size/body

enlarged spleen ( J:162388 )

• many mutant mice have splenomegaly

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
acute lymphoblastic leukemia		DOID:9952	OMIM:247640 OMIM:613065	J:162388

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/16/2024 MGI 6.23